An interview with Follicum’s CEO Jan Alenfall is now published on the company’s website. To access the video, please click here. For further information, please contact: Jan Alenfall – CEO, Follicum AB Telephone: +46 46 19 21 97 Email: info@follicum.com About Follicum AB Follicum is a biotech company focused on the discovery and development of […]
During spring we have reached two important milestones, one in each project. With regards to the hair project we have submitted a patent application for our unique topical formulation of FOL-005, and in the diabetes project we have chosen a candidate. Preparations for a clinical phase II-study with our unique topical formulation of FOL-005 in […]
What is your background and what have you done before joining Follicum? I have more than 35 years of experience in marketing and licensing within the global pharmaceutical industry. Today, I hold the position as Head of Nordic at Tesaro, an American biotech company in oncology, recently acquired by GSK. I have extensive experience from […]
Follicum AB (“Follicum” or “The Company”) today announces that a poster entitled “FOL-005 – modulation of hair growth in clinical studies” will be presented at the 11th World Congress for Hair Research scientific conference in Barcelona, April 24-27, 2019. This conference is one of the most important in the field bringing together the world’s leading […]
On 27 February 2019, Endpoints News published an article about Follicum: “Follicum, a Swedish biotech company born to find a treatment for hair loss, now has diabetes in its crosshairs”. Read the article For further information, please contact: Jan Alenfall – CEO, Follicum AB Telephone: +46 46 19 21 97 Email: info@follicum.com About Follicum AB […]
BioStock has performed a Status Report for Follicum, a peptide-specialized pharmaceutical company active in hair loss and diabetes. The full report is available via this link.
BioStock published an article about Follicum’s topical formulation on 7 February 2019 in Swedish. The article is here translated into English. Follicum develops FOL-005 to stimulate hair growth. The peptide-based candidate has recently undergone a phase IIa-study and the company was able to present positive top-line results during the fall. This summer a topical formulation of […]
BioStock published an article about Follicum’s diabetes project on 7 January 2019 in Swedish. The article is here translated into English. Follicum is currently running its flagship drug candidate for hair loss, FOL-005, through Phase II clinical trials and the company has recently received key patent extension in the United States as well as an “intention […]
The company has had a very intensive autumn and has finalized a number of important activities that have generated much attention. The key milestones are the successful completion of a new phase II study for stimulating hair growth, and at the same time, new preclinical data has been generated in the diabetes project. The results […]
Yesterday, Follicum presented top-line results from the First-In-Man scalp study with FOL-005 for stimulation of hair growth. The results confirm that the treatment is well tolerated and show that FOL-005 has the capacity to stimulate hair growth at optimal dosage. BioStock contacted the company’s CEO, Jan Alenfall, for further comments about the study and the […]